- Home
- MRVI vs NPCE Comparison
MRVI vs NPCE Comparison
Compare MRVI & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVI
- NPCE
- Stock Information
- Founded
- MRVI 2014
- NPCE 1997
- Country
- MRVI United States
- NPCE United States
- Employees
- MRVI N/A
- NPCE N/A
- Industry
- MRVI Biotechnology: Pharmaceutical Preparations
- NPCE Medical Specialities
- Sector
- MRVI Health Care
- NPCE Health Care
- Exchange
- MRVI Nasdaq
- NPCE Nasdaq
- Market Cap
- MRVI 376.2M
- NPCE 292.9M
- IPO Year
- MRVI 2020
- NPCE 2021
- Fundamental
- Price
- MRVI $2.88
- NPCE $10.32
- Analyst Decision
- MRVI Hold
- NPCE Strong Buy
- Analyst Count
- MRVI 9
- NPCE 6
- Target Price
- MRVI $5.25
- NPCE $16.67
- AVG Volume (30 Days)
- MRVI 967.6K
- NPCE 184.3K
- Earning Date
- MRVI 11-06-2025
- NPCE 11-11-2025
- Dividend Yield
- MRVI N/A
- NPCE N/A
- EPS Growth
- MRVI N/A
- NPCE N/A
- EPS
- MRVI N/A
- NPCE N/A
- Revenue
- MRVI $219,830,000.00
- NPCE $88,570,000.00
- Revenue This Year
- MRVI N/A
- NPCE $22.13
- Revenue Next Year
- MRVI $7.23
- NPCE $6.07
- P/E Ratio
- MRVI N/A
- NPCE N/A
- Revenue Growth
- MRVI N/A
- NPCE 23.32
- 52 Week Low
- MRVI $1.67
- NPCE $5.45
- 52 Week High
- MRVI $9.50
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- MRVI 62.30
- NPCE 65.86
- Support Level
- MRVI $2.61
- NPCE $9.65
- Resistance Level
- MRVI $2.98
- NPCE $10.12
- Average True Range (ATR)
- MRVI 0.17
- NPCE 0.41
- MACD
- MRVI 0.04
- NPCE 0.09
- Stochastic Oscillator
- MRVI 86.23
- NPCE 98.19
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.